跳至主要内容
临床试验/EUCTR2006-001299-19-GB
EUCTR2006-001299-19-GB进行中(未招募)1 期

Prospective randomised trial comparing intraoperative topical Quixil and intravenous tranexamic acid in reduction of blood loss following primary hip and knee joint replacement surgery - Tranexamic acid vs. Quixil - reducing blood loss in joint replacement

Golden Jubilee National Hospital0 个研究点目标入组 132 人开始时间: 2006年4月13日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
132

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Patients who will be having primary cemented total hip or knee joint replacement during the period of the study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Uncemented arthroplasty.
  • 2. Revision arthroplasty.
  • 3. Patients on anticoagulant (warfarin, low molecular weight heparin) or other medication known to affect clotting (except aspirin, which is to be given as part of standard DVT prophylaxis in all cases).
  • 4. Other drugs that may affect the activity of the drugs under investigation.
  • 5. Allergy to asprin (all patients to receive 150mg aspirin as standard DVT prophylaxis for 6 weeks).
  • 6. Patients with known coagulopathy (APTT or PT outside normal range pre-operatively).
  • 7. Previous reaction or ethical/religious objection to receiving blood products (Quixil contains a derivative of human blood).
  • 8. Pregnancy or breastfeeding.

研究者

相似试验